Low-Dose Interleukin-2 Combined With Rapamycin Led to an Expansion of CD4+CD25+FOXP3+Regulatory T Cells and Prolonged Human Islet Allograft Survival in Humanized Mice
- 1 August 2020
- journal article
- research article
- Published by American Diabetes Association in Diabetes
- Vol. 69 (8), 1735-1748
- https://doi.org/10.2337/db19-0525
Abstract
Islet transplantation is an emerging therapy for type 1 diabetes and hypoglycemic unawareness. However, a key challenge for islet transplantation is cellular rejection and the requirement for long-term immunosuppression. In this study, we established a diabetic humanized NOD-scidIL2R gamma(null)(NSG) mouse model of T-cell-mediated human islet allograft rejection and developed a therapeutic regimen of low-dose recombinant human interleukin-2 (IL-2) combined with low-dose rapamycin to prolong graft survival. NSG mice that had received renal subcapsular human islet allografts and were transfused with 1 x 10(7)of human spleen mononuclear cells reconstituted human CD45(+)cells that were predominantly CD3(+)T cells and rejected their grafts with a median survival time of 27 days. IL-2 alone (0.3 x 10(6)IU/m(2)or 1 x 10(6)IU/m(2)) or rapamycin alone (0.5-1 mg/kg) for 3 weeks did not prolong survival. However, the combination of rapamycin with IL-2 for 3 weeks significantly prolonged human islet allograft survival. Graft survival was associated with expansion of CD4(+)CD25(+)FOXP3(+)regulatory T cells (Tregs) and enhanced transforming growth factor-beta production by CD4(+)T cells. CD8(+)T cells showed reduced interferon-gamma production and reduced expression of perforin-1. The combination of IL-2 and rapamycin has the potential to inhibit human islet allograft rejection by expanding CD4(+)FOXP3(+)Tregs in vivo and suppressing effector cell function and could be the basis of effective tolerance-based regimens.Funding Information
- NHMRC (GNT1013185)
- University of Sydney
- Diabetes Australia and University of Sydney (GNT1158597, GNT1125456)
- JDRF/Australian Research Council (GNT10373210)
This publication has 49 references indexed in Scilit:
- Long-term liraglutide treatment is associated with increased insulin content and secretion in β-cells, and a loss of α-cells in ZDF ratsPharmacological Research, 2013
- Low-Dose Rapamycin Treatment Increases the Ability of Human Regulatory T Cells to Inhibit Transplant Arteriosclerosis In VivoAmerican Journal of Transplantation, 2012
- Regulation and function of mTOR signalling in T cell fate decisionsNature Reviews Immunology, 2012
- Adoptive Transfer With In Vitro Expanded Human Regulatory T Cells Protects Against Porcine Islet Xenograft Rejection via Interleukin-10 in Humanized MiceDiabetes, 2012
- Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kineticsBlood, 2011
- In vivo expansion of T reg cells with IL-2–mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppressionThe Journal of Experimental Medicine, 2009
- Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complexClinical and Experimental Immunology, 2009
- Local Production of IFN-γ by Invariant NKT Cells Modulates Acute Lyme CarditisThe Journal of Immunology, 2009
- Rapamycin Monotherapy in Patients With Type 1 Diabetes Modifies CD4+CD25+FOXP3+ Regulatory T-CellsDiabetes, 2008
- Combination of rapamycin and IL-2 increases de novo induction of human CD4+CD25+FOXP3+ T cellsJournal of Autoimmunity, 2008